Novo spent Monday 21 September in London telling investors what the company formerly known as Novo Nordisk intends to be in 2030, and the market told it what it thought: the shares fell as much as 9% during the Capital Markets Day, according to Reuters, and the New York-listed shares were down 6% on the day. The ambitions are large in absolute terms — more than five “multi-blockbuster” launches by 2030, more than DKK 150 billion of pipeline sales in 2035, more than 60 million patients served, and manufacturing capacity to put ten times as many people with obesity on an oral GLP-1 — but the growth target, revenue growth “in line with industry peers” over 2026–30, was read in Copenhagen as an admission that the years of double-digit expansion are over. For the Portugal ↔ Scandinavia corridor, which NorthSouth HQ flagged last week as the day to watch, three of those numbers matter more than the share price: the tenfold oral-capacity plan, the shift to a self-pay commercial model, and a headcount that is now 13,000 lower than a year ago.
What Novo committed to
The company’s own summary, issued from Bagsværd on the morning of the event, groups the 2030 ambitions under three headings. Under “grow and diversify pipeline”: launch more than five multi-blockbusters by 2030 and deliver more than DKK 150 billion of pipeline sales in 2035, a figure Novo describes as risk-adjusted, based on current pipeline assets and — management confirmed in the Q&A — excluding any future acquisitions; enter or complete at least five Phase 3 programmes in obesity and diabetes and at least five in other therapy areas. Under “drive sustainable growth”: a 2026–30 revenue compound annual growth rate in line with a named peer group of fourteen companies, from Eli Lilly and AstraZeneca to Pfizer and Bristol Myers Squibb; capacity to serve ten times more people with obesity on oral GLP-1; and more than 60 million patients globally by 2030. Under “deliver attractive returns”: a broadly stable operating margin and an attractive dividend per share. All of it is measured from a 2026 baseline, on adjusted metrics, and the company is explicit that none of it is financial guidance.
The statement also carries a quieter data point. It describes “approximately 66,000 employees”, where the rebrand announcement of 14 September spoke of “over 67,000”. In the presentations, according to the Financial Times and Reuters, management disclosed that total departures linked to the restructuring begun in 2025 have reached 13,000: the initial round of around 9,000 lay-offs, roughly 5,000 of them in Denmark out of a workforce that then numbered 78,400, plus some 4,000 subsequent exits that a spokesperson attributed mostly to natural attrition and roles left unfilled.
Why the shares fell
Analysts pressed chief executive Mike Doustdar and his team on two things: pricing power once semaglutide, the molecule behind Ozempic and Wegovy, loses exclusivity in the early 2030s, and what the company intends to do with its balance sheet. Markus Manns of Union Investment told Reuters the 2030 sales outlook and the stable-margin promise “failed to impress” and that management “did not say much” about the 2032 semaglutide patent cliff, while conceding that the case for the next-generation obesity drugs and the early pipeline was credible. Evan Seigerman of BMO wrote that the implied revenue growth of about 3.6% a year was already priced in, leaving the “burden of proof” on execution. Executives said the balance sheet could support larger acquisitions rather than only bolt-ons, and Doustdar said Novo would “not start with the size of the deal but with the quality of the asset”. The backdrop is a company whose shares have fallen more than 70% from their record highs, whose sales were DKK 309 billion in 2025, and whose US rival Eli Lilly is on track, on LSEG data cited by Reuters, to outsell Wegovy with Zepbound by upwards of $7 billion this year.
The product roadmap was more concrete than the financial one. CagriSema, the semaglutide-cagrilintide combination, is to launch early in 2027; standalone cagrilintide and a high-dose CagriSema follow in 2028; and zenagamtide, the next candidate, will now be launched in oral and injectable form simultaneously rather than shot-first, chief scientific officer Martin Holst Lange said. Novo wants at least five oral assets in clinical trials before the end of this year and, from 2027, to move up to fifteen programmes a year into human studies. It also published a CagriSema trial in people with type 2 diabetes in which a 1 mg dose delivered average weight loss of 12.4% against 9.1% for 5 mg of tirzepatide, Lilly’s molecule, as reported by the Financial Times.
| Novo, 2030 strategic ambitions (company statement, 21 September 2026) | Target |
|---|---|
| Multi-blockbuster launches by 2030 | More than five |
| Pipeline sales in 2035 (risk-adjusted, current assets, excluding M&A) | More than DKK 150 billion |
| Phase 3 programmes, obesity and diabetes / other therapy areas | At least five / at least five |
| Revenue CAGR 2026–30 | In line with fourteen named industry peers |
| Oral GLP-1 capacity for people with obesity | Ten times more people served |
| Patients served globally by 2030 | More than 60 million |
| Operating margin / dividend | Broadly stable / attractive per share |
| Workforce (statement wording) | Approximately 66,000; 13,000 departures since 2025 |
The two numbers that reach Portugal
The first is the manufacturing line. Doustdar said the company would scale production tenfold to be able to supply about 15 million patients with oral obesity therapies by the end of the decade, and Novo has already committed €432 million to convert its Athlone plant in Ireland to tablet production. Oral semaglutide depends on formulation and particle-engineering steps that are the specialism of Hovione, the Loures contract manufacturer that NorthSouth HQ has previously placed in the supply chain of Novo’s oral franchise. A tenfold capacity ambition is, for any external supplier in that chain, the single most important sentence of the day — more important than the margin guidance — because contract manufacturers are paid on volume, and the volume story is the part of the Novo narrative that management is doubling down on rather than defending.
The second is the commercial model. A Novo executive told the audience that out-of-pocket, self-pay channels now account for half of the entire Wegovy franchise and for 90% of demand for the Wegovy pill, which has passed seven million prescriptions in the United States. Portugal is exactly the kind of market that model was designed for: diabetes is reimbursed through the SNS, obesity treatment is largely paid for by patients, and the affiliate in Paço de Arcos — Novo Nordisk Comércio Produtos Farmacêuticos, Lda — already sells into a private-pay obesity market where the brand, not the prescriber, does much of the work. The consumer-facing “Novo” name unveiled last week and Monday’s pill-first roadmap are the same strategy seen from two angles, and the Portuguese affiliate will be one of the European organisations expected to execute it.
Where the cuts land
Novo does not break out the Portuguese headcount, and nothing on Monday singled out any European affiliate. What the 13,000 figure does establish is that the 2025 restructuring was not a one-off: a further 4,000 people left in the following year through attrition and hiring freezes, and the stable-margin ambition implies that cost discipline continues through 2030 even as commercial spending on obesity rises. For Nordic-owned pharmaceutical operations in Portugal, from Novo itself to Novonesis, LEO Pharma and Lundbeck, the signal is that headquarters will keep funding launches while trimming everything that is not a launch.
Why this matters for the corridor
Novo is the largest Nordic-owned healthcare operation in Portugal, the reference customer for the country’s most sophisticated pharmaceutical exporter, and through Novo Holdings one of the deepest pools of Danish capital looking for European assets — a pool that Monday’s comments about larger acquisitions make more relevant, not less. The market’s verdict on the Capital Markets Day was about growth arithmetic in Copenhagen. The corridor’s reading should be about volume in Loures and channel strategy in Paço de Arcos, and on both counts the day went better than the share price suggests. Danish pharmaceutical and medtech companies operating in Portugal are mapped in NorthSouth HQ’s Danish Companies in Portugal directory.